|
Ananda Pharma PLC - London-based biopharmaceutical company that develops regulatory-approved cannabinoid medicines to treat complex, chronic conditions - Begins trading on the OTCQB Venture Market in the US on Monday. Ananda will continue to also trade on its primary listing, the Apex segment of the Aquis Stock Exchange. Chief Executive Officer Melissa Sturgess says: ‘Following the recent appointment of Chris Tovey, the former [chief operating officer] of Nasdaq-listed GW Pharmaceuticals and Jazz Pharmaceuticals, and our engagement of Viridian Capital Partners in New York, the OTCQB listing is the third step of our US strategy. ‘As we start our world-leading cannabinoid clinical trials into a range of complex chronic conditions, we are focused on the US as the key market for commercializing future regulatory approved medicines. Increasing our visibility in this market is a crucial step and one I’m pleased we are making.’ Current stock price: 0.45 pence 12-month change: up 36% Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
